 |
|
FDA Approves Lethal Fluarix
Vaccine for Pediatric Use
The U.S. Food and Drug Administration approved use of the seasonal
influenza vaccine Fluarix for children ages 3 years to 17 years.
Previously, this vaccine, which contains inactivated influenza
A and B viruses, had been approved for use in adults, ages 18
years and older.
There are no long-term studies which establish the safety and
effectiveness of Fluarix for use in children ages 3 years and
older.
Fluarix is a seasonal influenza vaccine not intended to protect
against the 2009 H1N1 influenza virus.
With this approval, there are now four companies approved by
the FDA to manufacture seasonal influenza vaccine for use in children.
Influenza is more dangerous than the common cold for children,
who sometimes require medical care, especially if they are younger
than 5 years. Yet the FDA claims it is best to vaccinate children
each and every fall with chemicals that GlaxoSmithKline
lists as causing blood, lymphatic, cardiac, ear, eye, gastrointestinal,
immune, nervous, respiratory, muscular, allergic and vascular
disorders.
The above reactions are based on worldwide voluntary reports of
adverse events received for Fluarix since market introduction
of the vaccine. They do no include all reactions cause by the
vaccine diagnosed by Physicians worldwide.
Fluarix is manufactured by GlaxoSmithKline Biologicals of Dresden,
Germany.
|
|
|
